bromomethyl 4-methoxyphenyl ether | 121824-55-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: bromomethyl 4-methoxyphenyl ether
• 英文别名: 1-(Bromomethoxy)-4-methoxybenzene
• CAS: 121824-55-3
• 化学式: C₈H₉BrO₂
• 分子量: 217.062
• InChiKey: PRFSIBSPVUHQKD-UHFFFAOYSA-N

物化性质

• 沸点：
  271.0±20.0 °C(Predicted)
• 密度：
  1.441±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-甲氧基-4-[(甲硫基)甲氧基]苯 在 三甲基溴硅烷 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.17h， 生成 bromomethyl 4-methoxyphenyl ether
  参考文献：
  名称：

  Antonsen, Oeyvind; Benneche, Tore; Undheim, Kjell, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1988, vol. 42, # 8, p. 515 - 523

  摘要：

  DOI：

文献信息

• Process for the preparation of substituted pyrrolidine neuraminidase inhibitors
  申请人：——

  公开号：US20030055297A1

  公开（公告）日：2003-03-20

  A process for the preparation of neuraminidase inhibitors having structural formula (28) 1 or therapeutically acceptable salts thereof, in which R 1 is alkyl, cycloalkyl, cycloalkylalkyl, or arylalkyl; R 2 is alkyl, cycloalkyl, cycloalkylalkyl, or arylalkyl; R 4 is alkyl, cycloalkyalkyl, or aryl-(C 2 -C 4 -alkyl); R 10 is methyl, ethyl, iso-propyl, or vinyl; and R 12 is hydrogen or alkyl and intermediates useful for the process are disclosed.

  一种用于制备具有结构式（28）1或其治疗上可接受的盐的神经氨酸酶抑制剂的方法，其中R1是烷基，环烷基，环烷基烷基或芳基烷基；R2是烷基，环烷基，环烷基烷基或芳基烷基；R4是烷基，环烷烷基或芳基（C2-C4-烷基）；R10是甲基，乙基，异丙基或乙烯基；和R12是氢或烷基，公开了用于该方法的中间体。
• [EN] SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS<br/>[FR] BENZOPYRANES SUBSTITUES UTILES EN TANT QU'AGONISTES SELECTIFS DU RECEPTEUR BETA DES OESTROGENES
  申请人：LILLY CO ELI

  公开号：WO2004094401A1

  公开（公告）日：2004-11-04

  The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor ? agonists. Such agonists are useful for the treating Estrogen Receptor ? mediated diseases such as prostate cancer or BPH.

  本发明涉及取代苯并吡喃衍生物、立体异构体及其药学上可接受的盐以及其制备方法。本发明的化合物可用作雌激素受体β激动剂。这种激动剂对于治疗雌激素受体β介导的疾病，如前列腺癌或BPH等是有用的。
• [EN] OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS<br/>[FR] DERIVES OXINDOLES EN TANT QU'AGENTS DE LIBERATION DE L'HORMONE DE CROISSANCE
  申请人：SUMITOMO PHARMA

  公开号：WO2000010975A1

  公开（公告）日：2000-03-02

  An oxindole of Formula (1) or a prodrug thereof, or a pharmaceutically acceptable salt thereof is useful for growth hormone releaser wherein R?1, R2, R3, and R4¿ are independently hydrogen, optionally substituted alkyl, etc; R5 is optionally substituted aryl or optionally substituted heteroaryl; Z is -O- or -NH-; one of W?1 and W2¿ is hydrogen, alkyl or -Y-CON(R10)R11; the other of W?1 and W2¿ is (a); n is 1, 2 or 3; m is 0, 1, 2 or 3; Y is single bond or C¿1?-C3 alkylene; R?6 and R7¿ are independently hydrogen, optionally substituted alkyl, etc; R?8 and R9¿ are independently hydrogen, optionally substituted alkyl, etc; R?10 and R11¿ are independently hydrogen, alkyl etc.

  公式（1）的氧吲哚或其前药，或其药学上可接受的盐，可用作生长激素释放剂，其中R?1、R2、R3和R4¿独立地为氢、可选地取代的烷基等；R5为可选地取代的芳基或可选地取代的杂芳基；Z为-O-或-NH-；W?1和W2¿中的一个为氢、烷基或-Y-CON（R10）R11；W?1和W2¿中的另一个为（a）；n为1、2或3；m为0、1、2或3；Y为单键或C¿1?-C3烷基；R?6和R7¿独立地为氢、可选地取代的烷基等；R?8和R9¿独立地为氢、可选地取代的烷基等；R?10和R11¿独立地为氢、烷基等。
• N-(3-pyridylalkyl)sulfonamide derivative and pharmaceutical preparation containing thereof
  申请人：TERUMO KABUSHIKI KAISHA

  公开号：EP0501876A1

  公开（公告）日：1992-09-02

  Illustrative examples of the N-(3-pyridylalkyl)sulfonamide derivative are represented by the following formulae [II] and [III]: The derivatives are available for a thromboxane A₂ production inhibitor, a thromboxane A₂ antagonist, a prostaglandin H₂ antagonist, an anti-thrombus agent, a thrombus-preventing agent and an anti-allergy agent.

  N-(3-吡啶基烷基)磺酰胺衍生物的举例说明如下公式[II]和[III]所示：这些衍生物可用作血栓素A₂生成抑制剂、血栓素A₂拮抗剂、前列腺素H₂拮抗剂、抗血栓剂、预防血栓剂和抗过敏剂。
• NOVEL HETEROCYCLIC COMPOUNDS HAVING PLATELET AGGREGATION INHIBITORY EFFECTS
  申请人：MEIJI SEIKA KABUSHIKI KAISHA

  公开号：EP0897920A1

  公开（公告）日：1999-02-24

  Disclosed are a compound represented by the following formula (I) and pharmacologically acceptable salt and solvate thereof having inhibitory activity against platelet aggregation:    wherein A represents the following formula (II), (III), or (IV): A pharmaceutical composition comprising the above compound can be utilized as a platelet aggregation inhibitor that possesses excellent inhibitory activity against platelet aggregation, is free from hemorrhage and other side effects such as those derived from selectivity for the inhibitory action, and is potent against vasculature lesions, such as vasospasm.

  本发明公开了具有血小板聚集抑制活性的下式(I)代表的化合物及其药理学上可接受的盐和溶液： 其中 A 代表下式 (II)、(III) 或 (IV)： 由上述化合物组成的药物组合物可用作血小板聚集抑制剂，该药物对血小板聚集具有极佳的抑制活性，无出血和其他副作用，如抑制作用的选择性所产生的副作用，并对血管痉挛等血管病变具有强效作用。